The Links Between Executive and Linguistic Processes and Their Lesional Determinants From a Verbal Fluency Task (FluLEx)

Verbal fluency test require to produce as much words as possible in one or two minutes. This test is highly sensitive to main brain diseases and are therefore widely used in clinical routine for diagnostic purpose. The verbal fluency task requires several cognitive processes including executive and linguistic processes for which it is difficult to extract the origin of the deficit. For this reason, fluency tests are variably interpreted in terms of executive or language. The implementation of an experimental protocol exploring each of these processes separately and studying the links between the verbal fluency task and each of these processes should allow a better understanding of the origin of the verbal fluency deficit after brain injury and improve the identification of key brain structures.

Indeed, the lesion determinants of this task remain to be clarified despite remarkable advances due to the evolution of imaging techniques (voxel-based lesion-symptom mapping (VLSM); voxel-based morphometry (VBM)).

Furthermore, while the direct assessment of linguistic process, semantic memory, and processing speed is well defined, the examination of the executive component (i.e., strategic search process) remains unsettled and will be undertaken in this study.

This work will take advantage of data from previous multicenter work, validated methodologies for both analysis and interpretation of cognitive performance as well as anatomic-clinical correlations at the voxel level and will be performed in cognitive neurodegenerative and cerebrovascular disease.

Study Overview

• Status: Recruiting
• Conditions: Stroke; Cognitive Neurodegenerative; Verbal Fluency Disorders
• Intervention / Treatment: Diagnostic test: linguistic processes

• Study Type: Interventional
• Enrollment (Estimated): 88
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Martine ROUSSEL, PhD; Phone Number: 0322668240; Email: roussel.martine@chu-amiens.fr

Study Locations

• France
  • Amiens, France, 80054
    • Recruiting
    • CHU Amiens
    • Contact: Martine Roussel, PhD; Phone Number: 0322667813; Email: roussel.martine@chu-amiens.fr
    • Sub-Investigator: Olivier GODEFROY, Pr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• For Cognitive cortical neurodegenerative diseases PATIENTS
• informed consentPatients between 40 and 85 years old,
• French native language,
• Social Security affiliation,
• Can read, write and count (up to 36) and knows the alphabet
• Assessed in Amiens University Memory Clinic for:
• Mild severity impairment (MMSE> 19) or major severity impairment related to:
• AD according to Albert criteria and McKhann criteria
• DCL according to McKeith criteria
• FTLD according to Rascovsky criteria
• CBD according to Armstrong's criteria
• PSP according to Höglinger criteria
• For Stroke PATIENTS
• informed consent
• Patients between 40 and 85 years old,
• French native language,
• Social Security affiliation,
• Can read, write and count (up to 36) and knows the alphabet
• Having suffered a stroke, hospitalized in neurology, visualized by imaging

Exclusion Criteria:

• Mental retardation or guardianship
• Other current or past brain condition affecting cognition, including:
• Severe head trauma
• Epilepsy prior to stroke still requiring previous treatment
• Parkinson disease, multiple sclerosis
• Brain tumor or brain radiation therapy
• Current or past schizophrenia or psychosis
• Active or past psychiatric impairments requiring a stay> 2 days in a specialized environment
• Contra indication to MRI
• Comorbidity with life expectancy <1 year
• Comorbidity affecting cognition in particular:
• Alcohol (> 3 glasses / day) or history of alcohol withdrawal syndrome
• Opiate or cocaine addiction or opiate withdrawal syndrome
• Renal failure (dialysis or creatinine clearance <30)
• Hepatic failure (spontaneous INR> 1.5 or PT <60%)
• Respiratory failure requiring oxygen therapy
• Heart failure (orthopnea> 2 pillows)
• Persistent vigilance disorder (NIHSS1a score ≤1)
• Cancer with paraneoplastic syndrome
• Treatment with gold salts, D Penicillamine or other treatment with cognitive effect
• Patient under guardianship or curators or private under public law
• Pregnant and / or lactating woman

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Cognitive cortical neurodegenerative diseases and stroke PATIENTS

Diagnostic test: linguistic processes; Linguistic processes are assessed by performance score on the following tests: naming tests : BNT 34 (Colombo & Assal, 1992) and semantic naming adapted from the BECS-GRECO (Merck et al., 2011); vocabulary test (Mill Hill - Deltour, 1993),; repetition tests (Gremots - Bézy et al., 2016),; articulatory speed (Majerus, 2014 ; Roussel et al., 2012); semantic matching task adapted from the PPT (Howard & Patterson, 1992) and from the BECS-GRECO (Merck et al., 2011),; semantic categorization and attributes adapted from the BECS-GRECO (Merck et al., 2011),; phonologic and semantic research tasks adapted from the color TMT (D'helia et al., 1996)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Corelation between Linguistic test performance score and verbal fluency score	Linguistic processes are assessed by performance score on the following tests: BNT 34 and semantic naming adapted from the BECS-GRECO; vocabulary test; repetition tests; articulatory speed; semantic matching task adapted from the PPT and from the BECS-GRECO; semantic categorization and attributes adapted from the BECS-GRECO; phonologic and semantic research tasks adapted from the color TMT	1 hour

Collaborators and Investigators

• Sponsor: Centre Hospitalier Universitaire, Amiens

Study record dates

Study Major Dates

• Study Start (Actual): May 16, 2023
• Primary Completion (Estimated): June 1, 2024
• Study Completion (Estimated): June 1, 2024

Study Registration Dates

• First Submitted: May 16, 2023
• First Submitted That Met QC Criteria: May 16, 2023
• First Posted (Actual): May 25, 2023

Study Record Updates

• Last Update Posted (Actual): June 7, 2023
• Last Update Submitted That Met QC Criteria: June 6, 2023
• Last Verified: June 1, 2023

More Information

Terms related to this study

• Keywords: stroke; Verbal Fluency Disorders; cognitive neurodegenerative
• Additional Relevant MeSH Terms: Nervous System Diseases; Neurologic Manifestations; Neurobehavioral Manifestations; Language Disorders; Communication Disorders; Speech Disorders
• Other Study ID Numbers: PI2022_843_0150

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No